Company news
Shanghai Allist Pharmaceuticals Co. Ltd. news in 2025
Shanghai Allist Pharmaceuticals Co. Ltd.'s news releases, calls and decks from 2025, newest first.
Announcement on Voluntary Disclosure of Inclusion of Furmonertinib Mesylate Tablets for EGFR PACC-mutant NSCLC First-line Treatment in the Proposed Breakthrough Therapy Designation
December 25, 2025
Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management
December 15, 2025
Announcement on Voluntary Disclosure of the Inclusion of the Company’s Innovative Drugs in the Updated National Medical Insurance Catalog
December 7, 2025
Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
November 27, 2025
Announcement on Attending Three-Quarter Report Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction in 2025
November 4, 2025
Report for Q3 2025
October 28, 2025
Announcement on Result of Shareholding Reduction by Shareholder
September 24, 2025
Indicative Announcement on Change in Equity of Shareholder Reaching 1% Scale
September 12, 2025
Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
September 8, 2025
Announcement on Implementation of Semi-annual Dividend Distribution for 2025
September 2, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 26, 2025
Announcement on Shareholding Reduction Plan for Shareholders
August 8, 2025
Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process
July 9, 2025
Announcement on Voluntary Disclosure of Obtaining the 25th China Patent Gold Award
June 8, 2025
Announcement on Implementation of Dividend Distribution for 2024
May 22, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 14, 2025
Report for Q1 2025
April 23, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 25, 2025
Annual Earnings Preannouncement for 2024
January 20, 2025
Announcement on Voluntary Disclosure of Obtaining Notice of Drug Clinical Trial Approval for New Indications of Furmonertinib
January 17, 2025